Eosinophilic and Mast Cell Disorders
The interest in the science and practice of eosinophilic disorders and systemic mastocytosis (SM) has grown considerably in recent years. New developments have led to the reclassification of both eosinophilic disorders and SM into treatment-relevant categories. It is important to note for example that imatinib mesylate is ineffective, both in vitro and in vivo, against D816V c-kit-mutated SM as well as in the majority of patients with true hypereosinophilic syndrome (HES). It is hoped that the problem will be overcome by the therapeutic utilization of second-generation kinase inhibitors that have shown in vitro activity against D816V c-kit-mutated cell lines. However, much remains to be discovered in terms of both pathogenesis and treatment of SM and HES.This state-of-the art review of the science and practice of eosinophilic and mast cell disorders summarizes the current state of knowledge in the biology, classification, and treatment of primary eosinophilic disorders, including HES and SM. It is essential reading for hematologists, oncologists, allergists, immunologists, dermatologists, pulmonologists, cardiologists and gastroenterologists.
